Symbols / AZN Stock $187.72 +1.72% AstraZeneca PLC

Healthcare • Drug Manufacturers - General • United Kingdom • NYQ
AZN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. Pascal Claude Roland Soriot D.V.M., M…
Exch · Country NYQ · United Kingdom
Market Cap 291.13B
Enterprise Value 317.18B
Income 10.39B
Sales 60.44B
FCF (ttm) 6.54B
Book/sh 30.56
Cash/sh 4.96
Employees 96,100
Insider 10d —
IPO May 12, 1993
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 47.70%
P/E 28.23
Forward P/E 31.80
PEG 1.54
P/S 4.82
P/B 6.14
P/C —
EV/EBITDA 15.86
EV/Sales 5.25
Quick Ratio 0.70
Current Ratio 0.91
Debt/Eq 71.81
LT Debt/Eq —
EPS (ttm) 6.65
EPS next Y 5.90
EPS Growth 5.30%
Revenue Growth 12.50%
EPS Gr Q/Q 5.60%
Rev Gr Q/Q —
Earnings (next) 2026-07-27
Earnings (prior) 2026-04-29
ROA 8.47%
ROE 23.48%
ROIC —
Gross Margin 81.50%
Oper. Margin 28.17%
Profit Margin 17.19%
Shs Outstand 1.55B
Shs Float 1.54B
Insider Own 0.04%
Instit Own 59.69%
Short Float 0.12%
Short Ratio 0.88
Short Interest 1.83M
52W High 212.71
vs 52W High -11.75%
52W Low 134.14
vs 52W Low 39.94%
Beta 0.22
Impl. Vol. 1.56%
Rel Volume 0.68
Avg Volume 1.98M
Volume 1.35M
Target (mean) $224.49
Tgt Median $226.45
Tgt Low $184.00
Tgt High $245.00
# Analysts 10
Recom Strong_buy
Prev Close $184.54
Price $187.72
Change 1.72%
About

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$224.49
Mean price target
2. Current target
$187.72
Latest analyst target
3. DCF / Fair value
$75.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$187.72
Low
$184.00
High
$245.00
Mean
$224.49

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-02-13 up UBS Neutral → Buy —
2024-11-20 up UBS Sell → Neutral —
2024-09-11 up Erste Group Hold → Buy —
2024-08-12 main TD Cowen Buy → Buy $95
2024-05-30 main Argus Research Buy → Buy $85
2024-05-30 init Goldman Sachs — → Buy $97
2024-04-26 main BMO Capital Outperform → Outperform $82
2024-04-16 up Deutsche Bank Sell → Hold —
2024-02-12 main BMO Capital Outperform → Outperform $80
2024-02-08 down Deutsche Bank Buy → Hold —
2024-01-23 init Morgan Stanley — → Overweight $85
2024-01-03 down Jefferies Buy → Hold —
2023-09-25 up Jefferies Hold → Buy $80
2023-09-08 down Erste Group Buy → Hold —
2023-08-01 main BMO Capital Outperform → Outperform $83
2023-05-26 main Argus Research Buy → Buy $80
2023-04-13 main Argus Research — → Buy $85
2023-01-05 init BMO Capital — → Outperform $82
2022-11-14 main SVB Leerink — → Outperform $79
2022-11-11 main SVB Leerink — → Outperform $78
News
RSS: Latest AZN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-05 Soriot (Pascal) — — 101,495 — —
2026-03-04 Soriot (Pascal) — — 14,967 — —
2026-03-04 Sarin (Aradhana M.D.) — — 4,863 — —
2026-01-31 Investor AB — — 0 — —
2026-01-31 The Capital Group Companies, Inc. — — 0 — —
2026-01-31 BlackRock Financial Management, Inc. — — 0 — —
2026-01-31 Wellington Management Company, L.L.P. — — 0 — —
2025-12-31 Wallenberg (Marcus) — — 0 — —
2025-12-31 Wellington Management Company, L.L.P. — — 0 — —
2025-12-31 Rahman (Nazneen) — — 0 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
58,739.00
+8.63%
54,073.00
+18.03%
45,811.00
+3.29%
44,351.00
Operating Revenue
58,739.00
+8.63%
54,073.00
+18.03%
45,811.00
+3.29%
44,351.00
Cost Of Revenue
10,633.00
+4.17%
10,207.00
+23.45%
8,268.00
-33.27%
12,391.00
Reconciled Cost Of Revenue
10,633.00
+4.17%
10,207.00
+23.45%
8,268.00
-33.27%
12,391.00
Gross Profit
48,106.00
+9.67%
43,866.00
+16.84%
37,543.00
+17.47%
31,960.00
Operating Expense
34,779.00
+3.46%
33,615.00
+16.63%
28,821.00
+5.00%
27,448.00
Research And Development
14,232.00
+4.78%
13,583.00
+24.22%
10,935.00
+12.02%
9,762.00
Selling General And Administration
20,774.00
+2.72%
20,224.00
+10.99%
18,222.00
+1.32%
17,984.00
Selling And Marketing Expense
579.00
+4.32%
555.00
+2.97%
539.00
+0.56%
536.00
General And Administrative Expense
20,195.00
+2.67%
19,669.00
+11.23%
17,683.00
+1.35%
17,448.00
Other Operating Expenses
134.00
+10.74%
121.00
-26.22%
164.00
-18.00%
200.00
Total Expenses
45,412.00
+3.63%
43,822.00
+18.15%
37,089.00
-6.90%
39,839.00
Operating Income
13,327.00
+30.01%
10,251.00
+17.53%
8,722.00
+93.31%
4,512.00
Total Operating Income As Reported
13,743.00
+37.39%
10,003.00
+22.09%
8,193.00
+118.07%
3,757.00
EBITDA
19,506.00
+26.35%
15,438.00
+15.02%
13,422.00
+47.74%
9,085.00
Normalized EBITDA
19,139.00
+22.76%
15,591.00
+12.08%
13,911.00
+41.57%
9,826.00
Reconciled Depreciation
5,490.00
+8.39%
5,065.00
+2.66%
4,934.00
-6.09%
5,254.00
EBIT
14,016.00
+35.12%
10,373.00
+22.21%
8,488.00
+121.56%
3,831.00
Total Unusual Items
367.00
+339.87%
-153.00
+68.71%
-489.00
+34.01%
-741.00
Total Unusual Items Excluding Goodwill
367.00
+339.87%
-153.00
+68.71%
-489.00
+34.01%
-741.00
Special Income Charges
416.00
+267.74%
-248.00
+53.12%
-529.00
+29.93%
-755.00
Other Special Charges
-372.00
-3000.00%
-12.00
-233.33%
9.00
-98.43%
573.00
Impairment Of Capital Assets
—
—
—
0.00
Restructuring And Mergern Acquisition
-44.00
-116.92%
260.00
-50.00%
520.00
+185.71%
182.00
Net Income
10,225.00
+45.34%
7,035.00
+18.14%
5,955.00
+81.11%
3,288.00
Pretax Income
12,402.00
+42.70%
8,691.00
+25.97%
6,899.00
+175.85%
2,501.00
Net Non Operating Interest Income Expense
-1,254.00
+6.21%
-1,337.00
-3.80%
-1,288.00
-3.12%
-1,249.00
Interest Expense Non Operating
1,614.00
-4.04%
1,682.00
+5.85%
1,589.00
+19.47%
1,330.00
Net Interest Income
-1,254.00
+6.21%
-1,337.00
-3.80%
-1,288.00
-3.12%
-1,249.00
Interest Expense
1,614.00
-4.04%
1,682.00
+5.85%
1,589.00
+19.47%
1,330.00
Interest Income Non Operating
360.00
+4.35%
345.00
+14.62%
301.00
+271.60%
81.00
Interest Income
360.00
+4.35%
345.00
+14.62%
301.00
+271.60%
81.00
Tax Provision
2,169.00
+31.45%
1,650.00
+75.91%
938.00
+218.43%
-792.00
Tax Rate For Calcs
0.00
-5.19%
0.00
+39.64%
0.00
-28.44%
0.00
Tax Effect Of Unusual Items
66.06
+327.42%
-29.05
+56.31%
-66.49
+52.78%
-140.79
Net Income Including Noncontrolling Interests
10,233.00
+45.33%
7,041.00
+18.12%
5,961.00
+81.02%
3,293.00
Net Income From Continuing Operation Net Minority Interest
10,225.00
+45.34%
7,035.00
+18.14%
5,955.00
+81.11%
3,288.00
Net Income From Continuing And Discontinued Operation
10,225.00
+45.34%
7,035.00
+18.14%
5,955.00
+81.11%
3,288.00
Net Income Continuous Operations
10,233.00
+45.33%
7,041.00
+18.12%
5,961.00
+81.02%
3,293.00
Minority Interests
-8.00
-33.33%
-6.00
+0.00%
-6.00
-20.00%
-5.00
Normalized Income
9,924.06
+38.62%
7,158.95
+12.25%
6,377.51
+64.02%
3,888.21
Net Income Common Stockholders
10,225.00
+45.34%
7,035.00
+18.14%
5,955.00
+81.11%
3,288.00
Otherunder Preferred Stock Dividend
0.00
0.00
0.00
0.00
Diluted EPS
6.54
+45.33%
4.50
+18.11%
3.81
+80.57%
2.11
Basic EPS
6.60
+45.37%
4.54
+18.23%
3.84
+81.13%
2.12
Basic Average Shares
1,550.00
+0.00%
1,550.00
+0.06%
1,549.00
+0.06%
1,548.00
Diluted Average Shares
1,562.00
-0.06%
1,563.00
+0.06%
1,562.00
+0.13%
1,560.00
Diluted NI Availto Com Stockholders
10,225.00
+45.34%
7,035.00
+18.14%
5,955.00
+81.11%
3,288.00
Amortization
—
—
—
—
Depreciation Income Statement
—
—
—
—
Rent Expense Supplemental
452.00
+19.89%
377.00
+25.25%
301.00
+12.31%
268.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
114,074.00
+9.65%
104,035.00
+2.88%
101,119.00
+4.80%
96,483.00
Current Assets
28,723.00
+11.21%
25,827.00
+3.09%
25,054.00
+10.89%
22,593.00
Cash Cash Equivalents And Short Term Investments
5,719.00
+3.51%
5,525.00
-5.72%
5,860.00
-6.13%
6,243.00
Cash And Cash Equivalents
5,711.00
+4.06%
5,488.00
-6.03%
5,840.00
-5.29%
6,166.00
Cash Equivalents
4,379.00
+2.48%
4,273.00
-5.36%
4,515.00
-5.05%
4,755.00
Cash Financial
1,332.00
+9.63%
1,215.00
-8.30%
1,325.00
-6.09%
1,411.00
Other Short Term Investments
8.00
-78.38%
37.00
+85.00%
20.00
-74.03%
77.00
Accounts Receivable
10,237.00
+23.31%
8,302.00
-1.25%
8,407.00
+16.57%
7,212.00
Gross Accounts Receivable
10,289.00
+23.44%
8,335.00
-1.38%
8,452.00
+16.24%
7,271.00
Allowance For Doubtful Accounts Receivable
-52.00
-57.58%
-33.00
+26.67%
-45.00
+23.73%
-59.00
Other Receivables
2,906.00
-0.92%
2,933.00
+39.53%
2,102.00
+6.16%
1,980.00
Taxes Receivable
1,158.00
-37.71%
1,859.00
+30.36%
1,426.00
+95.08%
731.00
Inventory
6,557.00
+24.00%
5,288.00
-2.51%
5,424.00
+15.43%
4,699.00
Raw Materials
1,857.00
+24.71%
1,489.00
-2.74%
1,531.00
+7.67%
1,422.00
Work In Process
2,777.00
+21.69%
2,282.00
-1.85%
2,325.00
+24.73%
1,864.00
Finished Goods
1,923.00
+26.76%
1,517.00
-3.25%
1,568.00
+10.97%
1,413.00
Prepaid Assets
2,034.00
+17.10%
1,737.00
+7.42%
1,617.00
+21.67%
1,329.00
Restricted Cash
22.00
-82.95%
129.00
+26.47%
102.00
-37.04%
162.00
Assets Held For Sale Current
—
0.00
0.00
-100.00%
150.00
Hedging Assets Current
90.00
+66.67%
54.00
-53.45%
116.00
+33.33%
87.00
Other Current Assets
—
—
—
—
Total Non Current Assets
85,351.00
+9.13%
78,208.00
+2.82%
76,065.00
+2.94%
73,890.00
Net PPE
14,703.00
+26.24%
11,647.00
+10.90%
10,502.00
+11.14%
9,449.00
Gross PPE
25,245.00
+23.01%
20,522.00
+7.44%
19,101.00
+11.10%
17,192.00
Accumulated Depreciation
-10,542.00
-18.78%
-8,875.00
-3.21%
-8,599.00
-11.06%
-7,743.00
Properties
0.00
0.00
0.00
0.00
Land And Improvements
7,240.00
+10.03%
6,580.00
+1.72%
6,469.00
+18.92%
5,440.00
Buildings And Improvements
2,048.00
+28.97%
1,588.00
+17.46%
1,352.00
+14.38%
1,182.00
Machinery Furniture Equipment
11,156.00
+17.21%
9,518.00
+3.47%
9,199.00
+16.66%
7,885.00
Construction In Progress
4,740.00
+69.95%
2,789.00
+36.38%
2,045.00
-22.92%
2,653.00
Other Properties
61.00
+29.79%
47.00
+30.56%
36.00
+12.50%
32.00
Goodwill And Other Intangible Assets
59,088.00
+1.52%
58,202.00
+0.11%
58,137.00
-1.67%
59,127.00
Goodwill
21,242.00
+1.03%
21,025.00
+4.87%
20,048.00
+1.15%
19,820.00
Other Intangible Assets
37,846.00
+1.80%
37,177.00
-2.39%
38,089.00
-3.10%
39,307.00
Long Term Equity Investment
302.00
+12.69%
268.00
+82.31%
147.00
+93.42%
76.00
Other Investments
2,223.00
+36.21%
1,632.00
+6.67%
1,530.00
—
Non Current Deferred Taxes Assets
5,819.00
+8.83%
5,347.00
+13.33%
4,718.00
+44.59%
3,263.00
Non Current Prepaid Assets
559.00
+57.02%
356.00
+29.93%
274.00
+12.76%
243.00
Total Liabilities Net Minority Interest
65,355.00
+3.47%
63,164.00
+1.95%
61,953.00
+4.25%
59,425.00
Current Liabilities
30,617.00
+9.87%
27,866.00
-8.76%
30,542.00
+16.16%
26,293.00
Payables
7,501.00
-6.91%
8,058.00
+5.71%
7,623.00
+30.51%
5,841.00
Accounts Payable
3,820.00
+4.95%
3,640.00
+11.42%
3,267.00
+28.12%
2,550.00
Other Payable
2,017.00
-22.75%
2,611.00
+14.52%
2,280.00
+18.32%
1,927.00
Total Tax Payable
1,664.00
-7.91%
1,807.00
-12.96%
2,076.00
+52.20%
1,364.00
Current Debt And Capital Lease Obligation
3,013.00
+20.76%
2,495.00
-51.88%
5,185.00
-4.91%
5,453.00
Current Debt
2,631.00
+22.03%
2,156.00
-56.13%
4,914.00
-5.95%
5,225.00
Current Capital Lease Obligation
382.00
+12.68%
339.00
+25.09%
271.00
+18.86%
228.00
Total Non Current Liabilities Net Minority Interest
34,738.00
-1.59%
35,298.00
+12.37%
31,411.00
-5.19%
33,132.00
Long Term Debt And Capital Lease Obligation
26,136.00
-5.37%
27,619.00
+18.93%
23,222.00
-1.98%
23,690.00
Long Term Debt
24,715.00
-6.76%
26,506.00
+18.52%
22,365.00
-2.61%
22,965.00
Long Term Capital Lease Obligation
1,421.00
+27.67%
1,113.00
+29.87%
857.00
+18.21%
725.00
Long Term Provisions
918.00
-0.33%
921.00
-18.28%
1,127.00
+25.78%
896.00
Defined Pension Benefit
106.00
+7.07%
99.00
+7.61%
92.00
+2.22%
90.00
Non Current Pension And Other Postretirement Benefit Plans
1,105.00
-16.92%
1,330.00
-12.50%
1,520.00
+30.14%
1,168.00
Tradeand Other Payables Non Current
2,939.00
+51.26%
1,943.00
-25.75%
2,617.00
-23.92%
3,440.00
Non Current Deferred Revenue
55.00
0.00
-100.00%
7.00
-50.00%
14.00
Non Current Deferred Taxes Liabilities
3,500.00
+5.90%
3,305.00
+16.21%
2,844.00
-3.40%
2,944.00
Stockholders Equity
48,667.00
+19.32%
40,786.00
+4.20%
39,143.00
+5.69%
37,037.00
Common Stock Equity
48,667.00
+19.32%
40,786.00
+4.20%
39,143.00
+5.69%
37,037.00
Capital Stock
388.00
+0.00%
388.00
+0.00%
388.00
+0.26%
387.00
Common Stock
388.00
+0.00%
388.00
+0.00%
388.00
+0.26%
387.00
Share Issued
1,550.91
+0.02%
1,550.55
+0.02%
1,550.16
+0.02%
1,549.80
Ordinary Shares Number
1,550.76
+0.04%
1,550.10
0.00%
1,550.16
+0.02%
1,549.80
Treasury Shares Number
0.15
-66.64%
0.44
0.00
0.00
Additional Paid In Capital
35,419.00
+0.11%
35,379.00
+0.11%
35,341.00
+0.09%
35,308.00
Retained Earnings
10,972.00
+247.22%
3,160.00
+110.39%
1,502.00
+361.67%
-574.00
Minority Interest
52.00
-38.82%
85.00
+269.57%
23.00
+9.52%
21.00
Total Equity Gross Minority Interest
48,719.00
+19.20%
40,871.00
+4.35%
39,166.00
+5.69%
37,058.00
Total Capitalization
73,382.00
+9.05%
67,292.00
+9.40%
61,508.00
+2.51%
60,002.00
Working Capital
-1,894.00
+7.11%
-2,039.00
+62.85%
-5,488.00
-48.32%
-3,700.00
Invested Capital
76,013.00
+9.45%
69,448.00
+4.56%
66,422.00
+1.83%
65,227.00
Total Debt
29,149.00
-3.20%
30,114.00
+6.01%
28,407.00
-2.53%
29,143.00
Net Debt
21,635.00
-6.64%
23,174.00
+8.09%
21,439.00
-2.66%
22,024.00
Capital Lease Obligations
1,803.00
+24.17%
1,452.00
+28.72%
1,128.00
+18.36%
953.00
Net Tangible Assets
-10,421.00
+40.16%
-17,416.00
+8.31%
-18,994.00
+14.02%
-22,090.00
Tangible Book Value
-10,421.00
+40.16%
-17,416.00
+8.31%
-18,994.00
+14.02%
-22,090.00
Available For Sale Securities
2,212.00
+35.54%
1,632.00
+6.67%
1,530.00
+44.89%
1,056.00
Current Provisions
686.00
-45.94%
1,269.00
+23.44%
1,028.00
+42.38%
722.00
Derivative Product Liabilities
0.00
-100.00%
115.00
+202.63%
38.00
-95.97%
943.00
Financial Assets
498.00
+173.63%
182.00
-20.18%
228.00
+208.11%
74.00
Financial Assets Designatedas Fair Value Through Profitor Loss Total
11.00
0.00
0.00
-100.00%
10.00
Investmentin Financial Assets
2,223.00
+36.21%
1,632.00
+6.67%
1,530.00
+43.53%
1,066.00
Non Current Accrued Expenses
85.00
+30.77%
65.00
+80.56%
36.00
-2.70%
37.00
Preferred Shares Number
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
14,575.00
+22.88%
11,861.00
+14.65%
10,345.00
+5.48%
9,808.00
Net Income From Continuing Operations
12,402.00
+42.70%
8,691.00
+25.97%
6,899.00
+175.85%
2,501.00
Depreciation
1,283.00
+12.35%
1,142.00
+13.29%
1,008.00
-8.20%
1,098.00
Amortization Cash Flow
4,207.00
+7.24%
3,923.00
-0.08%
3,926.00
-5.53%
4,156.00
Depreciation And Amortization
5,490.00
+8.39%
5,065.00
+2.66%
4,934.00
-6.09%
5,254.00
Other Non Cash Items
1,819.00
+19.12%
1,527.00
+5.24%
1,451.00
+127.07%
639.00
Gain Loss On Investment Securities
49.00
+151.58%
-95.00
-137.50%
-40.00
-185.71%
-14.00
Net Foreign Currency Exchange Gain Loss
31.00
-26.19%
42.00
+23.53%
34.00
+112.50%
16.00
Gain Loss On Sale Of PPE
-168.00
-162.50%
-64.00
+74.50%
-251.00
-141.35%
-104.00
Change In Working Capital
-1,137.00
-27.32%
-893.00
-397.67%
300.00
-92.01%
3,757.00
Change In Receivables
-1,728.00
-6.40%
-1,624.00
-13.96%
-1,425.00
-5.63%
-1,349.00
Change In Inventory
-755.00
-476.34%
-131.00
+80.42%
-669.00
-116.98%
3,941.00
Change In Payable
1,346.00
+56.15%
862.00
-63.99%
2,394.00
+105.49%
1,165.00
Investing Cash Flow
-6,808.00
+14.69%
-7,980.00
-96.36%
-4,064.00
-37.30%
-2,960.00
Net PPE Purchase And Sale
-2,797.00
-49.65%
-1,869.00
-52.07%
-1,229.00
-51.92%
-809.00
Purchase Of PPE
-2,810.00
-46.05%
-1,924.00
-41.37%
-1,361.00
-24.75%
-1,091.00
Sale Of PPE
13.00
-76.36%
55.00
-58.33%
132.00
-53.19%
282.00
Capital Expenditure
-5,905.00
-28.76%
-4,586.00
-21.39%
-3,778.00
-46.95%
-2,571.00
Net Investment Purchase And Sale
-98.00
-916.67%
12.00
+271.43%
-7.00
+94.02%
-117.00
Purchase Of Investment
-229.00
-138.54%
-96.00
+29.41%
-136.00
+14.47%
-159.00
Sale Of Investment
131.00
+21.30%
108.00
-16.28%
129.00
+207.14%
42.00
Net Business Purchase And Sale
-1,240.00
+68.42%
-3,927.00
-233.08%
-1,179.00
-11.12%
-1,061.00
Purchase Of Business
-1,240.00
+68.53%
-3,940.00
-234.18%
-1,179.00
-11.12%
-1,061.00
Gain Loss On Sale Of Business
—
—
0.00
0.00
Net Intangibles Purchase And Sale
-2,959.00
-16.54%
-2,539.00
-19.43%
-2,126.00
-105.81%
-1,033.00
Purchase Of Intangibles
-3,095.00
-16.27%
-2,662.00
-10.14%
-2,417.00
-63.31%
-1,480.00
Net Other Investing Changes
—
—
190.00
—
Financing Cash Flow
-7,544.00
-88.79%
-3,996.00
+39.15%
-6,567.00
+3.75%
-6,823.00
Net Issuance Payments Of Debt
-1,650.00
-191.21%
1,809.00
+287.46%
-965.00
+19.38%
-1,197.00
Issuance Of Debt
15.00
-99.77%
6,492.00
+70.13%
3,816.00
0.00
Repayment Of Debt
-2,029.00
+56.38%
-4,652.00
+5.87%
-4,942.00
-288.83%
-1,271.00
Long Term Debt Issuance
15.00
-99.77%
6,492.00
+70.13%
3,816.00
0.00
Long Term Debt Payments
-2,029.00
+56.38%
-4,652.00
+5.87%
-4,942.00
-288.83%
-1,271.00
Net Long Term Debt Issuance
-2,014.00
-209.46%
1,840.00
+263.41%
-1,126.00
+11.41%
-1,271.00
Net Short Term Debt Issuance
364.00
+1274.19%
-31.00
-119.25%
161.00
+117.57%
74.00
Net Common Stock Issuance
-481.00
-1018.60%
-43.00
-230.30%
33.00
+13.79%
29.00
Common Stock Dividend Paid
-4,971.00
-7.39%
-4,629.00
-3.30%
-4,481.00
-2.68%
-4,364.00
Cash Dividends Paid
-4,971.00
-7.39%
-4,629.00
-3.30%
-4,481.00
-2.68%
-4,364.00
Net Other Financing Charges
-70.00
+91.43%
-817.00
+7.79%
-886.00
+15.38%
-1,047.00
Changes In Cash
223.00
+293.91%
-115.00
+59.79%
-286.00
-1244.00%
25.00
Effect Of Exchange Rate Changes
46.00
+149.46%
-93.00
-55.00%
-60.00
+25.00%
-80.00
Beginning Cash Position
5,429.00
-3.69%
5,637.00
-5.78%
5,983.00
-0.91%
6,038.00
End Cash Position
5,698.00
+4.95%
5,429.00
-3.69%
5,637.00
-5.78%
5,983.00
Free Cash Flow
8,670.00
+19.18%
7,275.00
+10.78%
6,567.00
-9.26%
7,237.00
Common Stock Issuance
-481.00
-1018.60%
-43.00
-230.30%
33.00
+13.79%
29.00
Interest Paid CFO
-1,316.00
-0.23%
-1,313.00
-21.46%
-1,081.00
-27.33%
-849.00
Interest Received CFI
286.00
-16.62%
343.00
+19.51%
287.00
+378.33%
60.00
Issuance Of Capital Stock
-481.00
-1018.60%
-43.00
-230.30%
33.00
+13.79%
29.00
Sale Of Business
0.00
-100.00%
13.00
0.00
0.00
Sale Of Intangibles
136.00
+10.57%
123.00
-57.73%
291.00
-34.90%
447.00
Taxes Refund Paid
-2,845.00
-3.45%
-2,750.00
-16.23%
-2,366.00
-45.78%
-1,623.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category